Karen Dominguez

Background: In 2022, 3100 adolescent girls and young women in sub-Saharan Africa experienced new HIV infections each week. HIV pre-exposure prophylaxis (PrEP) is effective at preventing HIV but has limited uptake and persistence. Mobile health (mHealth) interventions can improve medication adherence; however, their utility to improve PrEP adherence among adolescent girls and young women is not well established. Objective: This scoping review synthesizes evidence supporting mHealth for PrEP among adolescent girls and young women in sub-Saharan Africa and identifies strategies for further evaluation. Methods: We searched PubMed and Google Scholar databases, expert referrals, and reference lists using the following eligibility criteria: (1) original research study or protocol; (2) English language; (3) publication between January 1, 2012, and August 31, 2023; (4) inclusion of adolescent girls and young women; (5) conducted in sub-Saharan Africa; and (6) use of mHealth tools to promote PrEP uptake, adherence, or persistence. Titles and abstracts were screened by 2 independent researchers. Full-text manuscripts were reviewed against all eligibility criteria to determine the final included studies. The characteristics and results of the included studies were abstracted and synthesized by mHealth tool type. Results: The search identified 482 unique citations. Title and abstract review removed 380 citations primarily for not including adolescent girls and young women or being conducted outside sub-Saharan Africa. The remaining 102 articles underwent full-text review, yielding 31 eligible publications reporting on 21 unique studies. The most common mHealth tool was SMS text message (n=11), followed by app (n=9), telehealth (n=3), website (n=4), and video (n=1). Few publications evaluated effectiveness, and the results were mixed. One study found that SMS text message reminders improved PrEP adherence, and another concluded that SMS text message reminders did not show a significant impact. Two studies found that differentiated service delivery, which included mHealth components, improved PrEP uptake or persistence; however, the findings could not be attributed solely to the mHealth components. Lastly, 1 website was shown to improve PrEP persistence. Several earlier-stage studies focused on values and preferences toward mHealth without reporting the impact on PrEP. Conclusions: We found few rigorously evaluated mHealth interventions for supporting PrEP among adolescent girls and young women, preventing the ability to draw conclusions on its effectiveness. Studies documented high usability and acceptability but limited assessment of the impact on health outcomes. Secondary uses of mHealth were found for data collection and components of the standard of care. There is substantial room for growth in the innovative use of mHealth to support PrEP among adolescent girls and young women. Consideration of the strengths and limitations of mHealth tools in the local setting, review of past lessons learned, and intentional measurement of mHealth exposure and use could help advance this growing field.

BACKGROUND In 2022, 3100 adolescent girls and young women in sub-Saharan Africa experienced new HIV infections each week. HIV pre-exposure prophylaxis (PrEP) is effective at preventing HIV but has limited uptake and persistence. Mobile health (mHealth) interventions can improve medication adherence; however, their utility to improve PrEP adherence among adolescent girls and young women is not well established. OBJECTIVE This scoping review synthesizes evidence supporting mHealth for PrEP among adolescent girls and young women in sub-Saharan Africa and identifies strategies for further evaluation. METHODS We searched PubMed and Google Scholar databases, expert referrals, and reference lists using the following eligibility criteria: (1) original research study or protocol; (2) English language; (3) publication between January 1, 2012, and August 31, 2023; (4) inclusion of adolescent girls and young women; (5) conducted in sub-Saharan Africa; and (6) use of mHealth tools to promote PrEP uptake, adherence, or persistence. Titles and abstracts were screened by 2 independent researchers. Full-text manuscripts were reviewed against all eligibility criteria to determine the final included studies. The characteristics and results of the included studies were abstracted and synthesized by mHealth tool type. RESULTS The search identified 482 unique citations. Title and abstract review removed 380 citations primarily for not including adolescent girls and young women or being conducted outside sub-Saharan Africa. The remaining 102 articles underwent full-text review, yielding 31 eligible publications reporting on 21 unique studies. The most common mHealth tool was SMS text message (n=11), followed by app (n=9), telehealth (n=3), website (n=4), and video (n=1). Few publications evaluated effectiveness, and the results were mixed. One study found that SMS text message reminders improved PrEP adherence, and another concluded that SMS text message reminders did not show a significant impact. Two studies found that differentiated service delivery, which included mHealth components, improved PrEP uptake or persistence; however, the findings could not be attributed solely to the mHealth components. Lastly, 1 website was shown to improve PrEP persistence. Several earlier-stage studies focused on values and preferences toward mHealth without reporting the impact on PrEP. CONCLUSIONS We found few rigorously evaluated mHealth interventions for supporting PrEP among adolescent girls and young women, preventing the ability to draw conclusions on its effectiveness. Studies documented high usability and acceptability but limited assessment of the impact on health outcomes. Secondary uses of mHealth were found for data collection and components of the standard of care. There is substantial room for growth in the innovative use of mHealth to support PrEP among adolescent girls and young women. Consideration of the strengths and limitations of mHealth tools in the local setting, review of past lessons learned, and intentional measurement of mHealth exposure and use could help advance this growing field.

The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

Few studies have assessed HIV incidence in men who have sex with men (MSM) and transgender women (TGW) in sub-Saharan Africa (SSA). We assessed HIV incidence and its correlates among MSM and TGW in SSA enrolled in the prospective, multi-country HIV Prevention Trials Network (HPTN) 075 study, conducted from 2015 to 2017. Participants were enrolled at four sites in SSA (Kisumu, Kenya; Blantyre, Malawi; Cape Town and Soweto, South Africa). Eligible participants reported male sex assignment at birth, were 18 to 44 years of age, and had engaged in anal intercourse with a man in the preceding three months. Participation involved five study visits over 12 months. Visits included behavioral assessments and testing for HIV and sexually transmitted infections. Twenty-one of 329 persons acquired HIV during the study [incidence rate: 6.96/100 person-years (PY) (95% CI: 4.3, 10.6)]. Among TGW, HIV incidence was estimated to be 8.4/100 PY (95% CI: 2.3, 21.5). Four participants were found to have acute HIV infection at their first HIV-positive visit. HIV incidence varied among the four study sites, ranging from 1.3/100 PY to 14.4/100 PY. In multivariate longitudinal analysis, factors significantly associated with HIV acquisition were engagement in unprotected receptive anal intercourse [adjusted hazard ratio (AHR) 5.8, 95% confidence interval (CI): 2.4, 14.4] and incident rectal gonorrhea and/or chlamydia (AHR: 2.7, 95% CI: 1.1, 6.8). The higher HIV incidence in Cape Town compared to Blantyre could be explained by the higher prevalence of several risk factors for HIV infection among participants in Cape Town. Annual HIV incidence observed in this study is substantially higher than reported HIV incidence in the general populations in the respective countries and among MSM in the United States. Intensification of HIV prevention efforts for MSM and TGW in SSA is urgently needed.

Background: HealthMindr is a mobile phone HIV prevention app for men who have sex with men (MSM). In a previous pilot study, HealthMindr was found to be acceptable among users and to demonstrate preliminary effectiveness for increasing pre-exposure prophylaxis (PrEP) uptake among MSM. PrEP is a highly effective HIV prevention intervention; however, uptake remains low. Objective: To assess the efficacy of a mobile app for increasing PrEP uptake among MSM in the southern United States. Methods: In this randomized controlled trial, we will assess the efficacy of HealthMindr for increasing PrEP uptake among MSM in the following three southern US cities: Atlanta, Georgia; Jackson, Mississippi; and Washington, DC. In total, 657 men will be recruited and randomized to intervention and control arms in a 2:1 ratio. Participants in the intervention arm will receive access to the full HealthMindr app, with information and resources about PrEP (eg, frequently asked questions, risk assessment tool, and PrEP provider locator), other HIV prevention information, ability to order free HIV/sexually transmitted infection test kits, and additional resources related to substance use and mental health. Participants in the control arm will use the HealthMindr app but will only have access to the study timeline and a message center to communicate with study staff. Participants will complete quarterly surveys to assess self-reported PrEP uptake over 12 months of follow-up. Self-reported PrEP uptake will be verified by dried blood spot testing and/or uploading a photograph of a PrEP prescription. Results: Participant recruitment is expected to begin in January 2020. Conclusions: This trial will determine whether the HealthMindr app can increase PrEP uptake among MSM in the southern United States. Trial Registration: ClinicalTrials.gov NCT03763942; https://clinicaltrials.gov/ct2/show/NCT03763942 International Registered Report Identifier (IRRID): PRR1-10.2196/16231

Pre-exposure prophylaxis (PrEP) is highly efficacious for preventing HIV but has not yet been brought to scale among at-risk persons. In several clinical trials in urban areas, technology-based interventions have shown a positive impact on PrEP adherence. In rural and small-town areas in the United States, which often do not have geographically proximal access to PrEP providers, additional support may be needed. This may be particularly true for younger persons who are more likely to face multiple barriers to accessing PrEP services. Home-based care, accomplished through a tailored mobile phone app, specimen self-collection (SSC), and interactive video consultations, could increase both PrEP initiation and persistence in care. The goal of this study is to assess the initiation and persistence in PrEP care for those randomized to a home-care intervention (electronic PrEP, ePrEP) relative to those assigned to the standard of care (control) condition. We will conduct additional assessments, including quantitative and qualitative analyses, to contextualize trial results and facilitate scale-up. This 2-arm, randomized controlled trial will enroll young men who have sex with men (YMSM) aged between 18 and 24 years from rural areas of Georgia, Mississippi, and North Carolina. The trial will seek to recruit a diverse sample, targeting 50% participation among highly impacted groups of black or Latino men who have sex with men. Intervention participants will receive a study app that incorporates a messaging platform, a scheduling and milestone-based tracking system for PrEP care progress, electronic behavioral surveys, and interactive video consultations with a clinician. Complemented by SSC kits mailed to laboratories for standard PrEP-related monitoring, the ePrEP system will allow participants to access PrEP care without leaving their homes. YMSM randomized to the control condition will receive a listing of nearest local PrEP providers to receive standard PrEP care. Both groups will complete quarterly electronic surveys. The primary outcome, assessed at 6 and 12 months after randomization, will be the difference in the proportion of intervention versus control participants that achieve protective levels of the active metabolite of oral PrEP (tenofovir diphosphate in dried blood spots). Enrollment will begin in May 2019, with study completion in 2022. This trial will determine whether home PrEP care provided through an app-based platform is an efficacious means of expanding access to PrEP care for a diverse group of YMSM in rural and small-town areas of the United States. ClinicalTrials.gov NCT03729570; https://clinicaltrials.gov/ct2/show/NCT03729570 (Archived by WebCite at http://www.webcitation.org/78RE2Qizf). PRR1-10.2196/13982.